MCM3AP-AS1 regulates proliferation, apoptosis, migration, and invasion of breast cancer cells via binding with ZFP36.

BACKGROUND: Previous studies suggest that long noncoding RNA (lncRNA) maintenance complex component 3 associated protein (MCM3AP) antisense RNA 1 (MCM3AP-AS1) has a wide range of functions in several cancers. However, its expression and functions in breast cancer are unclear.
METHODS: Reverse transcription polymerase chain reaction (RT-PCR) was used to detect the expression of MCM3AP-AS1. MTT, colony formation and anchorage-independent growth assay were used to examine the effect of MCM3AP-AS1 on growth of breast cancer cells. TUNEL and flow cytometry assay were applied to investigate the role of MCM3AP-AS1 on cell apoptosis. Wound heading and transwell matric penetration assay were used to detect the role of MCM3AP-AS1 on cell motility. RNA pull-down and RIP assay were used to examine the interaction of MCM3AP-AS1 and ZFP36.
RESULTS: We found that lncRNA MCM3AP-AS1 was significantly upregulated in breast cancer, which correlated with patients' clinicopathological characteristics. Downregulation of MCM3AP-AS1 substantially inhibited the proliferation, apoptosis, migration, and invasion of breast cancer cells. Further analysis clarified that MCM3AP-AS1 binds with the RNA-binding protein ZFP36 ring finger protein (ZFP36) to regulate the levels of cyclin D1 (CCND1), c-myc (MYC), and matrix metalloproteinase 1 (MMP1).
CONCLUSIONS: Our findings show lncRNA MCM3AP-AS1 might be a prognostic factor and a promising therapeutic target for breast cancer therapy. 2021 Translational Cancer Research. All rights reserved.

Introduction

In 2018, about 2.1 million new cases of female breast cancer were reported globally, which accounted for almost 25% of cancer cases among women. Breast cancer is the most commonly occurring cancer in 154 out of 185 countries. It is also the leading cause of cancer death among women in more than 100 countries (1). Therefore, breast cancer is an important health issue worldwide, and there is an urgent need to explore its underlying mechanisms to develop novel therapies to treat patients with breast cancer.

Dysregulation of oncogenes and tumor suppressor genes plays an important role in breast cancer tumorigenesis and progression (2). This occurs in a context in which 70% of the human genome is identified as encoding noncoding RNAs (ncRNAs) (2,3). ncRNAs are classified into two categories, long ncRNAs (lncRNAs) and small ncRNAs, according to their transcript length (4). LncRNAs are larger than 200 nt in length, and research suggests that lncRNAs are involved in many physiological and pathological processes (5), in which they might act as transcriptional modulators, splicing regulators, posttranscriptional processors, enhancers, molecular decoys for miRNAs, chromatin remodelers, or as a guide for protein-protein, protein-DNA, and protein-RNA interactions (6-8). The functions of lncRNAs in cancer attracted our interest, because multiple lncRNAs are dysregulated in cancer. Xue et al. demonstrated that lncRNA HOTAIR is upregulated in tamoxifen-resistant breast cancer tissues, and that upregulation of HOTAIR increased estrogen receptor (ER) levels and its downstream gene regulation to induce tamoxifen resistance (9). Tan et al. showed that lncRNA NORAD is downregulated and is closely correlated with lymph node metastases of and poor prognosis in breast cancer (10). Li et al. found that lncRNA NEAT1 is upregulated in breast cancer and can promote the invasion of breast cancer cells via the microRNA miR-211/high mobility group AT-hook 2 (HMGA2) axis (11). Several studies showed that lncRNA maintenance complex component 3 associated protein (MCM3AP) antisense RNA 1 (MCM3AP-AS1) is implicated in the progression of hepatocellular carcinoma (12), glioblastoma (13), papillary thyroid cancer (14), and pancreatic (15), prostate (16), and breast cancer (17). Chen et al. showed MCM3AP-AS1 is reported to be overexpressed in breast cancer, and MCM3AP/miR-28-5p/CENPF axis accelerates breast cancer progression. However, the authors didn’t investigate the expression of MCM3AP-AS1 in breast cancer tissues, and whether MCM3AP is involved in other mechanisms in breast cancer is unclear (17). Previous studies suggest that lncRNA MCM3AP-AS1 has important and wide-ranging functions in cancer progression. The above-mentioned reports showed that MCM3AP-AS1 might play an important role in cancer progression. However, the mechanisms of lncRNA MCM3AP-AS1 in breast cancer tissues remains unclear, and its expression and mechanisms are yet to be clarified.

ZNF36 encodes a member of the Kruppel C2H2-type zinc-finger family of proteins. This encoded protein may function as a transcription factor that regulates the expression of GABA type-A receptors. Elevated expression of this gene has been observed in gastric cancer and the encoded protein may stimulate migration and invasion of human gastric cancer cells (18). Silencing of ZNF36 induces apoptosis in human gastric cancer cells (19).

The present study aimed to determine the expression status of lncRNA MCM3AP-AS1 in breast cancer tissues, and its relationship with the clinical characteristics of patients with breast cancer. We also studied the effect of downregulation of MCM3AP-AS1 expression on breast cancer cell viability, migration, and invasion. Moreover, we sought to determine the binding partner(s) of MCM3AP-AS1.

We present the following article in accordance with the MDAR reporting checklist (available at https://dx.doi.org/10.21037/tcr-21-1940).

Methods

Cells and tissue specimens

The breast cancer cells ZR-75-30 and MDA-MB-231 were purchased from Shanghai Institutes for Biological Sciences Cell Resource Centre (Shanghai, China), and cultured using Dulbecco’s modified Eagle medium (DMEM; ThermoFisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco, Grand Island, NY, USA). All cells were cultured in a humidified incubator containing 5% CO2 at 37 °C.

A total of 30 paired breast cancer and corresponding adjacent normal tissues (ANTs) were collected from the Weihai Municipal Hospital. Before collection, patient consent and approval from the Institutional Research Ethics Committee of Weihai Municipal Hospital were obtained. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). None of the patients received any pre-operative therapy. Clinicopathological stage and tumor-node-metastasis (TNM) classifications were evaluated following the criteria stipulated by the American Joint Committee on Cancer (AJCC).

Quantitative real-time polymerase chain reaction (qPCR) and plasmids

The total RNA was extracted using TRIzol (Invitrogen, Waltham, MA, USA). The nuclear and cytoplasmic fractions were extracted using a MinuteTM Cytoplasmic and Nuclear Extraction Kit (Invent Biotechnologies, Plymouth, MN, USA). qPCR was performed on a 7500 Fast Real Time PCR system (Applied Biosystems, Foster City, CA, USA) using the SYBR Green PCR Kit (Invitrogen, Waltham, MA, USA). The primers used were as follows: MCM3AP-AS1, forward, 5'- GCTGCTAATGGCAACACTGA-3', reverse, 5'- AGGTGCTGTCTGGTGGAGAT-3'; cyclin D1 (CCND1), forward, 5'-TCTACACCGACAACTCCATCCG-3', reverse, 5'- TCTGGCATTTTGGAGAGGAAGTG-3'; c-myc (MYC), forward, 5'-CCTGGTGCTCCATGAGGAGAC-3', reverse, 5'-CAGACTCTGACCTTTTGCCAGG-3'; matrix metalloproteinase 1 (MMP1), forward, 5'-ATGAAGCAGCCCAGATGTGGAG-3', reverse, 5'-TGGTCCACATCTGCTCTTGGCA-3'.

A lentivector-mediated short-hairpin RNA (shRNA) targeting MCM3AP-AS1 (sh-1 and sh-2) and scrambled plasmids (sh-control) were designed and synthesized by Geneseed Biotech (Guangzhou, China). The process of screening stable cell lines was performed according to previously published methods (12).

Western blotting assay

Extracted proteins were subjected to western blotting according to previously described methods (20). Equal amounts of protein (25 μg/well) were separated using 10.5% polyacrylamide gels and transferred onto polyvinylidene fluoride (PVDF) membranes. Subsequently, the membranes were probed with primary antibodies (diluted 1:2,500, Abcam, Cambridge, MA, USA) and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody (diluted 1:1,500, Abcam, Cambridge, UK). β-actin was used as the loading control of total protein.

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay

We seeded cells into 96-well plates, put the plates into a cell incubator, and collected the cells at the specified time points. Subsequently, we dyed the cell with 50 μL MTT reagent for 4 h. The MTT produced blue crystals formazan. We then dissolved the crystals using 100 μL dimethyl sulfoxide (DMSO). We finally detected the cell absorbance using a falcon microplate reader (BD-Labware, San Jose, CA, USA) at 540 nm wavelength.

Colony formation assay

We seeded the cells into 12-well plates, and put the plates into a 37 °C humidified incubator. The cells were cultured for 10 days, and we changed the cell culture every day. When the cell culture was finished, we fixed the cell colonies formed using 4% paraformaldehyde for 5 min. We then dyed the colonies using 0.1% crystal violet for 30 min and finally examined and quantified the colonies with a light microscope.

Anchorage-independent growth assay

We coated 6-well plates using a mixture including complete cell medium and 1% agar and placed a mixture of 5×102 cells, 2 mL complete medium, and 0.3% agar onto the coated plates. Then, the plates were incubated in a 37 °C humidified incubator for 10 days. Finally, we quantified the colonies larger than 0.1 mm.

Terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) assay

We seeded the breast cancer cells on coverslips, and put the coverslips into 24-well plates. The plates were maintained in a humidified incubator containing 5% CO2 at 37 °C for 24 h. Then, sorafenib were used to treat the cells for another 24 h. We subsequently fixed the cells using 4% paraformaldehyde and used a mixture of 0.1% sodium citrate and 0.1% Triton-X-100 to permeabilize the cells. The DNA fragmentation was probed using the TUNEL kit following the manufacturer’s instructions (Roche Applied Science, Penzberg, Germany). Finally, we captured the fluorescent images using an EVOS fluorescence microscope (AMG, Bothwell, WA, USA).

Flow cytometry

We seeded the cells into 10 cm plates and put the cells into a humidified cell incubator for 72 h. We subsequently collected the cells, washed them twice using phosphate-buffered saline (PBS), and resuspended them with binding buffer. Then, we added a mixture of fluorescein isothiocyanate (FITC) annexin V/RNase A and propidium iodide to the cell plates. The cells were maintained at room temperature in the dark. Thirty min later, the cells were examined using a flow cytometer (Beckman-Coulter, Indianapolis, IN, USA).

Wound healing assay

We seeded the cells into 6-well plates and put the plates in a humidified incubator containing 5% CO2 at 37 °C until they reached 90% confluence. Then, we scratched the cell layer using a sterile 10 μL pipette tip. At 0 and 24 h, we detected the width of the scratch under a microscope (CKX41; Olympus, Tokyo, Japan).

Transwell matrix penetration assay

We coated the transwell filter chamber with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) and put the chamber into the 24-well plates after adding cell medium. Then, we seeded 1×104 cells into the upper chamber containing cell medium and 10% FBS (HyClone, Logan, UT, USA). The cells were maintained in a humidified cell incubator for 24 h. We subsequently removed the cells inside the upper chamber with cotton swabs. Then, we used 1% paraformaldehyde to fix the invaded cells for 10 min and used hematoxylin to stain the cells for 5 min. Finally, we used a microscope (CKX41; Olympus) to examine and quantify the invaded cells in 10 randomly chosen fields.

RNA pull-down and RNA immunoprecipitation (RIP) assays

RNA pull-down and RIP assays were performed according to previously described methods (21).

Statistical analysis

The statistical analysis was performed using SPSS version 20.0 (IBM Corp., Armonk, NY, USA), and the data are presented as means ± standard deviations. Student’s paired t-tests were used to analyze the statistical differences between paired tissues, and comparisons among two unpaired groups were analyzed using independent samples t-test. The statistical analysis between sh-1/2 and sh-control were performed using analysis of variance (ANOVA) followed by Dunnett’s test. The correlations of lncRNA MCM3AP-AS1 and patients’ clinicopathological characteristics were analyzed using the χ2 test. P<0.05 was considered as indicating statistically significant differences. Each experiment was performed three times independently.

Results

LncRNA MCM3AP-AS1 is upregulated in breast cancer and is closely related to patients’ clinical characteristics

Through analyzing data from the public dataset The Cancer Genome Atlas (TCGA; https://cancergenome.nih.gov/), we found that lncRNA MCM3AP-AS1 was significantly upregulated in breast cancer (). Meanwhile, we determined the expression of MCM3AP-AS1 in 30 fresh paired breast cancer tissues. As demonstrated in , the expression of MCM3AP-AS1 was markedly upregulated in breast cancer tissues compared with that in the corresponding ANT. In addition, we investigated the correlation between MCM3AP-AS1 expression and the clinical characteristics of patients with breast cancer. Statistical analysis suggested that the MCM3AP-AS1 expression level was closely associated with clinical stage (P=0.001), tumor (T) classification (P<0.001), node (N) classification (P=0.024), and metastasis (M) classification (P=0.002) (). Finally, we detected the expression of MCM3AP-AS1 in transformed mammary epithelial HBL100 cells and breast cancer cell lines (T-47D, MDA-MB-231, BT-474, BT-20, SK-BR-3, ZR-75-30 and MCF7) using qPCR. The results showed that the expression of MCM3AP-AS1 in breast cancer cells was upregulated significantly compared with that in the normal transformed mammary epithelial cells (). The above analysis showed that MCM3AP-AS1 is significantly increased in breast cancer and might be a prognostic factor for poor prognosis of patients with breast cancer.

Figure 1

LncRNA MCM3AP-AS1 is significantly increased in breast cancer tissues. (A) The mRNA expression of MCM3AP-AS1 in normal breast tissues and breast cancer tissues using data from the TCGA. (B) The mRNA expression of MCM3AP-AS1 in 30 paired fresh breast cancer tissues. (C) The mRNA expression of MCM3AP-AS1 in in transformed mammary epithelial HBL100 cells, and breast cancer cell lines T-47D, MDA-MB-231, BT-474, BT-20, SK-BR-3, ZR-75-30, and MCF7. **, P<0.01. ***, P<0.001. LncRNA, long noncoding RNA; MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1; mRNA, messenger RNA; TCGA, The Cancer Genome Atlas; ANT, adjacent normal breast tissue.

Table 1

Correlation between the clinicopathological features and expression of MCM3AP-AS1

Patient characteristics	MCM3AP-AS1 expression		P value
	Low	High
Age (years)			0.149
≤53	17	4
>53	5	4
Clinical stage			0.001
I–II	19	2
III–IV	3	6
T classification			<0.001
T1–T2	21	3
T3–T4	1	5
N classification			0.024
N0	13	1
N1–N3	9	7
M classification			0.002
M0	22	5
M1	0	3
Vital status			0.896
Alive	17	6
Dead	5	2

MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1; T, tumor; N, node; M, metastasis.

Downregulation of MCM3AP-AS1 inhibits cell growth and induces apoptosis of breast cancer cells

MCM3AP-AS1 levels were closely correlated with the T classification; therefore, we explored the biological functions of MCM3AP-AS1 related to breast cancer growth. First, MCM3AP-AS1 was stably knocked down in MDA-MB-231 and ZR-75-30 cells using a specific shRNA (). Subsequently, MTT assays showed that downregulation of MCM3AP-AS1 substantially suppressed the proliferation of MDA-MB-231 and ZR-75-30 cells (). Colony formation () and anchorage-independent growth assays () also demonstrated that MCM3AP-AS1 knockdown significantly inhibited the growth of MDA-MB-231 and ZR-75-30 cells. In addition, TUNEL assays and flow cytometry illustrated that the percentage of apoptotic cells was significantly upregulated in MCM3AP-AS1-silenced breast cancer cells (). Moreover, knockdown of MCM3AP-AS1 induced cell cycle arrest at the G1 phase in MDA-MB-231 and ZR-75-30 cells (). Taken together, these findings suggest that downregulation of MCM3AP-AS1 significantly inhibits the proliferation and cell cycle transition of breast cancer cells, leading to their apoptosis.

Figure 2

Downregulation of MCM3AP-AS1 inhibits cell growth and induces apoptosis of breast cancer cells. (A) Relative expression of MCM3AP-AS1 in the indicated stable cell lines. (B) Downregulation of MCM3AP-AS1 substantially inhibits the proliferation of MDA-MB-231 (left panel) and ZR-75-30 (right panel) using the MTT assay. (C) Representative images (left panel) and quantitative analysis (right panel) of the indicated cell lines using colony formation assays. (D) Representative images (left panel) and quantitative analysis (right panel) of the indicated cell lines using anchorage-independent growth assays. (E) Downregulation of MCM3AP-AS1 increases the number of TUNEL ± cells compared with the scramble group under the treatment with sorafenib. (F) Representative image of apoptotic cells from a flow cytometry assay. (G) Apoptotic cells in different cell lines. (H) Flow cytometry assay showing that downregulation of MCM3AP-AS1 results in cell cycle G1 phase arrest in MDA-MB-231 (left panel) and ZR-75-30 (right panel) cells. (I) The representative image of cell cycle. *, P<0.05; **, P<0.01; ***, P<0.001. MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TUNEL, terminal deoxynulceotidyl transferase nick-end-labeling.

Downregulation of MCM3AP-AS1 suppresses the migration and invasion of breast cancer cells

MCM3AP-AS1 levels were related to the N and M classifications; therefore, we further checked the biological roles of MCM3AP-AS1 in migration and invasion of breast cancer. As shown in , downregulation of MCM3AP-AS1 significantly reduced the migration and invasion of breast cancer cells, as assessed using wound healing and transwell assays, respectively. Thus, knockdown of MCM3AP-AS1 significantly inhibited the migration and invasion of breast cancer cells.

Figure 3

Downregulation of MCM3AP-AS1 suppresses the migration and invasion of breast cancer cells. (A) Representative image (left panel) and quantitative analysis (right panel) of wound healing and transwell assays stained by hematoxylin using MDA-MB-231 cells, respectively. (B) Representative image (left panel) and quantitative analysis (right panel) of wound healing and transwell assays stained by hematoxylin using ZR-75-30 cells, respectively. *, P<0.05; **, P<0.001. MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1.

MCM3AP-AS1 mainly located in the nucleus

The location of RNA is regarded as an important clue to its function (22). Therefore, we used the long noncoding (lnc) ATLAS website (http://lncatlas.crg.eu/) to analyze the subcellular location of MCM3AP-AS1. As shown in , MCM3AP-AS1 was mainly located in the nucleus, which was confirmed using cell lines. We performed a cytoplasmic and nuclear extraction experiment, and then detected the level of MCM3AP-AS1 in the cytoplasm and nucleus. The results showed that MCM3AP-AS1 was mainly located in the nucleus ().

Figure 4

MCM3AP-AS1 can directly bind with the RNA-binding protein ZFP36. (A) Analysis of MCM3AP-AS1 subcellular location using the lnc ATLAS website. (B) MCM3AP-AS1 levels in the nucleus and cytoplasm. (C) An RNA pull-down assay showing that ZFP36 can bind directly with MCM3AP-AS1. (D) An RIP assay showing that MCM3AP-AS1 is enriched in the lysate pulled down by an antibody recognizing ZFP36. (E) mRNA levels of CCND1, MYC, and MMP1 are significantly decreased in MCM3AP-AS1-silenced cells as assessed using qPCR assay using MDA-MD-231 cells. (F) mRNA levels of CCND1, MYC, and MMP1 are significantly decreased in MCM3AP-AS1-silenced cells as assessed using qPCR assay using ZR-75-30 cells. **, P<0.01; ***, P<0.001. MCM3AP-AS1, maintenance complex component 3 associated protein antisense RNA 1; ZFP36, ZFP36 ring finger protein; lnc, long noncoding; mRNA, messenger RNA; CCND1, cyclin D1; MYC, c-myc; MMP1, matrix metalloproteinase 1; qPCR, quantitative real-time polymerase chain reaction; RIP, RNA immunoprecipitation.

MCM3AP-AS1 can directly bind with RNA-binding protein ZFP36 ring finger protein (ZFP36)

To investigate the molecular mechanisms of MCM3AP-AS1’s effects on breast cancer progression, we predicted its binding protein through analyzing a public dataset, the database of RNA-Binding Protein Specificities (RBPDB; http://rbpdb.ccbr.utoronto.ca/index.php). We found that the binding protein that has the highest score is RNA-binding protein ZFP36. Next, we verified the prediction using molecular experiments. An RNA pull-down assay illustrated that ZFP36 was present in the complexes pulled down using biotinylated MCM3AP-AS1 but was not present in the complexes pulled down using immunoglobulin G (IgG) (). Correspondingly, an RIP assay also demonstrated that MCM3AP-AS1 was enriched in the lysate pulled down using the antibody recognizing ZFP36, but not in the lysate pulled down using IgG (). The RNA pull-down and RIP assays suggested that lncRNA MCM3AP-AS1 can bind with ZNF36. ZNF36 is a member of a small family of tandem Cys3His zinc finger proteins and promotes rapid decay of adenylate-uridylate-rich elements (ARE)-containing messenger RNA (mRNA) (23,24). ZNF36 can regulate several oncogenes and growth factors such as CCND1, MMP1, and MYC (25,26). Therefore, we detected the mRNA of CCND1, MYC, and MMP1. As shown in , the mRNA levels of CCND1, MYC, and MMP1 decreased significantly in MCM3AP-AS1-silenced cells. Taken together, these results show that lncRNA MCM3AP-AS1 can bind with RNA-binding protein ZFP36 to regulate the expressions of CCND1, MYC, and MMP1.

Discussion

To date, multiple lncRNAs have been discovered using functional genomics research. LncRNAs interact with DNA, RNA, or proteins to play crucial functions in many biological processes and diseases at the transcriptional or post-transcriptional level (27). Therefore, it is important to explore potential lncRNAs that might serve as prognostic factors or therapeutic targets. Consequently, we combined data from previous studies and a publicly available dataset and found that lncRNA MCM3AP-AS1 plays an important and wide-ranging role in the progression of multiple cancers. The results of the present study showed that lncRNA MCM3AP-AS1 expression is increased significantly in breast cancer tissues. Further correlation analysis of clinicopathological characteristics and MCM3AP-AS1 showed that MCM3AP-AS1 is closely related with clinical stage and TNM classification, suggesting that MCM3AP-AS1 might be a prognostic factor for poor prognosis of patients with breast cancer. Chen et al. showed that MCM3AP-AS1 is upregulated in breast cancer cells and can regulate CENPF expression (17). However, their studies did not include correlation analysis of MCM3AP-AS1 with clinical features in breast cancer tissues. Our study extended our understanding of the importance of MCM3AP-AS1 in breast cancer. However, the number of specimens analyzed in the present study was low; therefore, we will increase the number of specimens in our future study.

LncRNAs can function as oncogenes or tumor suppressors. Alterations of lncRNAs promote tumorigenesis and metastasis (28). The widely studied LncRNA HOTAIR is involved in breast cancer progression, such as via epithelial-to-mesenchymal transition (EMT) (29), metastasis (30), and tamoxifen resistance (9). LncRNA SNAR also regulates proliferation, migration, and invasion in breast cancer (31,32). Our study showed that lncRNA MCM3AP-AS1 is involved in breast cancer progression. Downregulation of MCM3AP-AS1 significantly inhibited the proliferation, migration, invasion, and cell cycle transition, leading to breast cancer cell apoptosis. However, the in vivo functions of MCM3AP-AS1 in breast cancer require further clarification in future studies.

Most lncRNAs exert their biological role in association with RNA-binding proteins, which can interact with multiple different RNAs (33). Corresponding, our study showed that MCM3AP-AS1 can bind with ZNF36 through RNA pull-down and RIP assays in breast cancer cells. It has been reported that ZNF36 can function as a transcription factor, and can interact with AREs through tandem CCCH zinc fingers in the initiation and development of cancers through modulating mRNA decay (34,35). Our study showed that ZFP36 can further regulate the expression of oncogenes such as CCND1, MYC, and MMP1 on transcription level. Our findings showed that lncRNA MCM3AP-AS1 might be a promising therapeutic target in breast cancer. However, we aim to investigate other mechanisms of lncRNA MCM3AP-AS1 in breast cancer progression in our future research.